The TRAIL to cancer therapy: hindrances and potential solutions
Apoptosis is an ordered and orchestrated cellular process that occurs in physiological and pathological conditions. Resistance to apoptosis is a hallmark of virtually all malignancies. Despite being a cause of pathological conditions, apoptosis could be a promising target in cancer treatment. Tumor...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2019
|
| Online Access: | http://psasir.upm.edu.my/id/eprint/82608/ http://psasir.upm.edu.my/id/eprint/82608/1/The%20TRAIL%20to%20cancer%20therapy%20hindrances%20and%20potential%20solutions.pdf |
| _version_ | 1848859314105614336 |
|---|---|
| author | Wong, Sonia How Ming Kong, Wei Yang Fang, Chee Mun Loh, Hwei San Chuah, Lay Hong Abdullah, Syahril Ngai, Siew Ching |
| author_facet | Wong, Sonia How Ming Kong, Wei Yang Fang, Chee Mun Loh, Hwei San Chuah, Lay Hong Abdullah, Syahril Ngai, Siew Ching |
| author_sort | Wong, Sonia How Ming |
| building | UPM Institutional Repository |
| collection | Online Access |
| description | Apoptosis is an ordered and orchestrated cellular process that occurs in physiological and pathological conditions. Resistance to apoptosis is a hallmark of virtually all malignancies. Despite being a cause of pathological conditions, apoptosis could be a promising target in cancer treatment. Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), also known as Apo-2 ligand (Apo2L), is a member of TNF cytokine superfamily. It is a potent anti-cancer agent owing to its specific targeting towards cancerous cells, while sparing normal cells, to induce apoptosis. However, resistance occurs either intrinsically or after multiple treatments which may explain why cancer therapy fails. This review summarizes the apoptotic mechanisms via extrinsic and intrinsic apoptotic pathways, as well as the apoptotic resistance mechanisms. It also reviews the current clinically tested recombinant human TRAIL (rhTRAIL) and TRAIL receptor agonists (TRAs) against TRAIL-Receptors, TRAIL-R1 and TRAIL-R2, in which the outcomes of the clinical trials have not been satisfactory. Finally, this review discusses the current strategies in overcoming resistance to TRAIL-induced apoptosis in pre-clinical and clinical settings. |
| first_indexed | 2025-11-15T12:27:22Z |
| format | Article |
| id | upm-82608 |
| institution | Universiti Putra Malaysia |
| institution_category | Local University |
| language | English |
| last_indexed | 2025-11-15T12:27:22Z |
| publishDate | 2019 |
| publisher | Elsevier |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | upm-826082020-11-14T20:39:41Z http://psasir.upm.edu.my/id/eprint/82608/ The TRAIL to cancer therapy: hindrances and potential solutions Wong, Sonia How Ming Kong, Wei Yang Fang, Chee Mun Loh, Hwei San Chuah, Lay Hong Abdullah, Syahril Ngai, Siew Ching Apoptosis is an ordered and orchestrated cellular process that occurs in physiological and pathological conditions. Resistance to apoptosis is a hallmark of virtually all malignancies. Despite being a cause of pathological conditions, apoptosis could be a promising target in cancer treatment. Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), also known as Apo-2 ligand (Apo2L), is a member of TNF cytokine superfamily. It is a potent anti-cancer agent owing to its specific targeting towards cancerous cells, while sparing normal cells, to induce apoptosis. However, resistance occurs either intrinsically or after multiple treatments which may explain why cancer therapy fails. This review summarizes the apoptotic mechanisms via extrinsic and intrinsic apoptotic pathways, as well as the apoptotic resistance mechanisms. It also reviews the current clinically tested recombinant human TRAIL (rhTRAIL) and TRAIL receptor agonists (TRAs) against TRAIL-Receptors, TRAIL-R1 and TRAIL-R2, in which the outcomes of the clinical trials have not been satisfactory. Finally, this review discusses the current strategies in overcoming resistance to TRAIL-induced apoptosis in pre-clinical and clinical settings. Elsevier 2019-11 Article PeerReviewed text en http://psasir.upm.edu.my/id/eprint/82608/1/The%20TRAIL%20to%20cancer%20therapy%20hindrances%20and%20potential%20solutions.pdf Wong, Sonia How Ming and Kong, Wei Yang and Fang, Chee Mun and Loh, Hwei San and Chuah, Lay Hong and Abdullah, Syahril and Ngai, Siew Ching (2019) The TRAIL to cancer therapy: hindrances and potential solutions. Critical Reviews in Oncology/Hematology, 143. pp. 81-94. ISSN 1040-8428 10.1016/j.critrevonc.2019.08.008 |
| spellingShingle | Wong, Sonia How Ming Kong, Wei Yang Fang, Chee Mun Loh, Hwei San Chuah, Lay Hong Abdullah, Syahril Ngai, Siew Ching The TRAIL to cancer therapy: hindrances and potential solutions |
| title | The TRAIL to cancer therapy: hindrances and potential solutions |
| title_full | The TRAIL to cancer therapy: hindrances and potential solutions |
| title_fullStr | The TRAIL to cancer therapy: hindrances and potential solutions |
| title_full_unstemmed | The TRAIL to cancer therapy: hindrances and potential solutions |
| title_short | The TRAIL to cancer therapy: hindrances and potential solutions |
| title_sort | trail to cancer therapy: hindrances and potential solutions |
| url | http://psasir.upm.edu.my/id/eprint/82608/ http://psasir.upm.edu.my/id/eprint/82608/ http://psasir.upm.edu.my/id/eprint/82608/1/The%20TRAIL%20to%20cancer%20therapy%20hindrances%20and%20potential%20solutions.pdf |